Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of single-dose 500 mg mebendazole chewable tablet in children 2–10 years
2015-001226-42Phase 3
- Sponsor
- Johnson & Johnson
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mebendazole in Soil-Transmitted Helminthiases (STH) and gastrointestinal helminthiasis, sponsored by Johnson & Johnson. Primary endpoint: Adverse events profile.
02
Drugs
mebendazole
03
Conditions
Soil-Transmitted Helminthiases (STH)gastrointestinal helminthiasis
Beyond the preview
Go deeper on 2015-001226-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001226-42.